SAN DIEGO, April 11, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Ocugen, Inc. (NASDAQ:OCGN) securities between May 8, 2020 and April 1, 2024. Ocugen, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to cure blindness diseases.
For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
The Allegations: Robbins LLP is Investigating the Allegations that Ocugen, Inc. (OCGN) Lacked Proper Internal Controls Over Financial Reporting
According to the complaint, during the class period, defendants failed to disclose that Ocugen's financial statements from May 8, 2020 to the present were materially misstated and Ocugen did not have adequate internal controls.
Plaintiff alleges that on April 1, 2024, Ocugen announced that "the Audit Committee of the Board of Directors (the "Audit Committee"), based on the recommendation of management and after consultation with EY, concluded that the Company's previously-issued audited consolidated financial statements for ...